HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
August 08, 2022
Share
HLB Pharmaceutical Co., Ltd announced a private placement of series 15 unregistered coupon non guaranteed private convertible bond for the gross proceeds of KRW 20,000,000,000 on August 9, 2022. The transaction will include participation from JW Holdings Corporation , Prime Life & Health Co., Ltd. and DongKoo Bio & Pharma Co., Ltd. The bonds carry coupon rate of 2% and maturity rate of 2% and will mature on August 10, 2025. The bonds are 100% convertible into 1,329,345 registered common shares of the company at conversion price of KRW 15,045 per share.
The conversion period will start on August 10, 2023 and end on July 10, 2025. The payment date is August 10, 2022. The transaction was approved by board of directors of the company.
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
DONGKOO BIO & PHARMA CO., LTD. 
